Wugen is a Biotech company based in St. Louis, Missouri. It has raised $200M in total funding. Latest round: Series B.
Wugen funding overview
Wugen is a Biotech company based in St. Louis, Missouri. Wugen has raised $200M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series B announced in July 2021. The round record for Wugen runs through 2021; nothing later has been disclosed. Investors on record include Abingworth, Tybourne Capital Management, Fidelity Management & Research Company, Intermediate Capital Group, Sands Capital, Aisling Capital Management and 6 others. 12 distinct backers are named across the disclosed rounds.
Wugen at a glance
Total raised
$200M
Latest round
Series B
Latest round date
July 2021
Industry
Biotech
Headquarters
St. Louis, Missouri
Notable investors
Abingworth, Tybourne Capital Management, Fidelity Management & Research Company, Intermediate Capital Group, Sands Capital, Aisling Capital Management, Alexandria Venture Investments, Velosity Capital
Frequently asked about Wugen funding
How much has Wugen raised?
Wugen has raised $200M in total disclosed funding across the rounds on record.
Who has invested in Wugen?
Abingworth, Tybourne Capital Management, Fidelity Management & Research Company, Intermediate Capital Group, Sands Capital, Aisling Capital Management are named among the investors backing Wugen.
What was the latest Wugen funding round?
The most recent disclosed round is a Series B, announced in July 2021.
Where is Wugen based?
Wugen is based in St. Louis, Missouri.
What sector does Wugen operate in?
Wugen is tracked under Biotech from St. Louis, Missouri, with $200M in disclosed funding.
When did Wugen last raise?
The last disclosed Wugen round closed in July 2021 at Series B.
Every Wugen figure above comes from filings and announced rounds in the StartupFundraising company database and is revised as new rounds are recorded. The lists below compare Biotech companies in St. Louis at a similar stage.
